Vivos Therapeutics (VVOS) Shares Outstanding (Weighted Average) (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $14.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $14.6 million, up 70.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 70.26% YoY), and the FY2025 annual result was $10.3 million, up 104.66% from the prior year.
• Shares Outstanding (Weighted Average) improved to $14.6 million in Q1 2026 per VVOS's latest filing, from $10.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $21.2 million in Q1 2022 and troughed at $849446.0 in Q3 2022.
• A 5-year average of $6.8 million and a median of $4.3 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Weighted Average) sank 100.0% in 2022, then soared 311.67% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $920592.0 in 2022, then jumped by 32.46% to $1.2 million in 2023, then soared by 311.67% to $5.0 million in 2024, then soared by 104.66% to $10.3 million in 2025, then soared by 42.44% to $14.6 million in 2026.
• Business Quant data shows VVOS's Shares Outstanding (Weighted Average) at $14.6 million in Q1 2026, $10.3 million in Q4 2025, and $9.6 million in Q3 2025.